| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | EpCAM |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6552H10080N1740O2052S46 |
| Molar mass | 147533.60 g·mol−1 |
  (what is this?) (verify) | |
Adecatumumab (MT201) is a recombinant human IgG1 monoclonal antibody which is used to target tumor cells. It binds to the epithelial cell adhesion molecule (EpCAM - CD326), with the intent to trigger antibody-dependent cellular cytotoxicity. It was developed by Micromet Inc, which was acquired by Amgen.[1]
Adecatumumab has been used in clinical studies of treatment in colorectal, prostate[2] and breast cancers.[3] Phase II results were published in 2010.[4]
- ^ "Adecatumumab - Amgen/Merck Serono". Adis Insight. Springer Nature Switzerland AG.
- ^ Oberneder R, Weckermann D, Ebner B, Quadt C, Kirchinger P, Raum T, et al. (October 2006). "A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients". European Journal of Cancer. 42 (15): 2530–8. doi:10.1016/j.ejca.2006.05.029. PMID 16930989.
- ^ Prang N, Preithner S, Brischwein K, Göster P, Wöppel A, Müller J, et al. (January 2005). "Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines". British Journal of Cancer. 92 (2): 342–9. doi:10.1038/sj.bjc.6602310. PMC 2361858. PMID 15655555.
- ^ Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix L, et al. (February 2010). "An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer". Annals of Oncology. 21 (2): 275–82. doi:10.1093/annonc/mdp314. PMID 19633042.